Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 350Stomach Neoplasms 31Neoplasm Metastasis 30Breast Neoplasms, Male 25Neoplasms 16Inflammatory Breast Neoplasms 12Brain Neoplasms 12Carcinoma, Non-Small-Cell Lung 10Esophageal Neoplasms 7Prostatic Neoplasms 6Pancreatic Neoplasms 6Urinary Bladder Neoplasms 5Rectal Neoplasms 5Adenocarcinoma 5Sarcoma 4Lung Neoplasms 4HER2-positive Breast Cancer 4Endometrial Neoplasms 4Colorectal Neoplasms 4Colonic Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 3Triple Negative Breast Neoplasms 3Salivary Gland Neoplasms 3Head and Neck Neoplasms 3HER2 Positive Breast Cancer 3Cardiotoxicity 3Carcinoma, Renal Cell 3Carcinoma, Ovarian Epithelial 3Carcinoma, Hepatocellular 3Carcinoma, Ductal, Breast 3

Interventions

seribantumab 2zenocutuzumab 1patritumab 1exemestane 1Vinorelbine 1Trastuzumab 1Letrozole 1In Situ Hybridization, Fluorescence 1Fulvestrant 1Erlotinib Hydrochloride 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lethal Congenital Contracture Syndrome 2 × Trastuzumab × Clear all
NCT03321981 2024-03-07

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Merus B.V.

Phase 2 Completed
105 enrolled 23 charts

Lethal Congenital Contracture Syndrome 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡